Phase1 Clinical Trial of OTS102 in Subjects with Solid Tumors - Phase1 Clinical Trial of OTS102 in Subjects with Solid Tumors

OncoTherapy Science, Inc.0 个研究点目标入组 18 人开始时间: 2012年7月9日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)symptomatic brain metastasis 2)pleural effusion, ascites fluid, pericardial fluid requiring drenege 3)Unhealed traumatic lesion 4)Hemorrhagic diathesis or severe coagulopthy, and patients with those histories 5)hemoptysis or lung hemorrhage or gastrointestinal bleeding, and patients with those histories 6)uncontrolled hypertension (systolic:140 mmHg and over, diastolic: 90 mmHg and over), or serious arrhythmia or heart failure 7)serious complication, equivalent to CTCAE grade 3 or greater 8)Patients who require systemic administration of the following agents during OTS102 study medication period. -Corticosteroid, Anticoagulant drug, Immunosuppresant, Immunostimulant -Granulocyte Colony Stimulating Factor (G-CSF), Granulocyte, Macrophage Colony Stimulating Factor (GM-CSF), Erythropoietin (EPO) 9)Participating in drug clinical trials 10)Woman who is pregnant, breast feeding and child-bearing potential. 11)Patient or patient's partner unwilling to use adequate contraception. 12)As determined by the principal investigator or the sub-investigator the subject has difficulties that would prevent the subject's ability to participate in the trial.

发起方